Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria

<p>Abstract</p> <p>Background</p> <p>Despite clear emphasis through the Millennium Development Goals, the problem of high maternal mortality persists especially within low and middle income countries. Various studies report remarkably high maternal mortality rates in no...

Full description

Bibliographic Details
Main Authors: Okereke Ekechi, Ahonsi Babatunde, Tukur Jamilu, Ishaku Salisu, Oginni Ayodeji
Format: Article
Language:English
Published: BMC 2012-08-01
Series:BMC Research Notes
Subjects:
Online Access:http://www.biomedcentral.com/1756-0500/5/421
id doaj-97280c9a262b4f64827b2f0ed694d922
record_format Article
spelling doaj-97280c9a262b4f64827b2f0ed694d9222020-11-25T01:36:18ZengBMCBMC Research Notes1756-05002012-08-015142110.1186/1756-0500-5-421Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern NigeriaOkereke EkechiAhonsi BabatundeTukur JamiluIshaku SalisuOginni Ayodeji<p>Abstract</p> <p>Background</p> <p>Despite clear emphasis through the Millennium Development Goals, the problem of high maternal mortality persists especially within low and middle income countries. Various studies report remarkably high maternal mortality rates in northern Nigeria, where maternal mortality rates exceed 1,000 deaths per 100,000 live births and eclampsia contributes approximately 40% of maternal deaths. Across Nigeria, diazepam is routinely used for the management of eclampsia. Prior to February 2008, diazepam was widely used for the management of eclampsia in Kano State (within northern Nigeria) with case fatality rate being over 20%. While magnesium sulphate (MgSO<sub>4</sub>) is recognized as the most effective drug for the management of eclampsia; this study aims to compare MgSO<sub>4</sub> therapy with diazepam therapy in terms of case fatality rates and costs.</p> <p>Findings</p> <p>This retrospective study, including 1045 patients with eclampsia and pre-eclampsia during the years 2008 and 2009, reports a drop in case fatality rates from 20.9% (95% CI: 18.7, 23.2) to 2.3% (95% CI: 1.4, 3.2) among eclampsia patients following the MgSO<sub>4</sub> intervention. The study observed no significant difference in the cost of using MgSO<sub>4</sub> therapy compared to diazepam therapy.</p> <p>Conclusions</p> <p>The study found a remarkable reduction in case fatality rate due to eclampsia in those who received MgSO<sub>4</sub> therapy with minimal increase in costs when compared to diazepam therapy. Concerted efforts should be focused on properly introducing MgSO<sub>4</sub> into emergency obstetric protocols especially within developing countries to reduce maternal mortality and also impact on health system performance.</p> http://www.biomedcentral.com/1756-0500/5/421Magnesium sulphateMaternal mortalityMillennium Development goalsNorthern Nigeria
collection DOAJ
language English
format Article
sources DOAJ
author Okereke Ekechi
Ahonsi Babatunde
Tukur Jamilu
Ishaku Salisu
Oginni Ayodeji
spellingShingle Okereke Ekechi
Ahonsi Babatunde
Tukur Jamilu
Ishaku Salisu
Oginni Ayodeji
Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
BMC Research Notes
Magnesium sulphate
Maternal mortality
Millennium Development goals
Northern Nigeria
author_facet Okereke Ekechi
Ahonsi Babatunde
Tukur Jamilu
Ishaku Salisu
Oginni Ayodeji
author_sort Okereke Ekechi
title Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
title_short Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
title_full Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
title_fullStr Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
title_full_unstemmed Benefits of using magnesium sulphate (MgSO<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from Kano State in Northern Nigeria
title_sort benefits of using magnesium sulphate (mgso<sub>4</sub>) for eclampsia management and maternal mortality reduction: lessons from kano state in northern nigeria
publisher BMC
series BMC Research Notes
issn 1756-0500
publishDate 2012-08-01
description <p>Abstract</p> <p>Background</p> <p>Despite clear emphasis through the Millennium Development Goals, the problem of high maternal mortality persists especially within low and middle income countries. Various studies report remarkably high maternal mortality rates in northern Nigeria, where maternal mortality rates exceed 1,000 deaths per 100,000 live births and eclampsia contributes approximately 40% of maternal deaths. Across Nigeria, diazepam is routinely used for the management of eclampsia. Prior to February 2008, diazepam was widely used for the management of eclampsia in Kano State (within northern Nigeria) with case fatality rate being over 20%. While magnesium sulphate (MgSO<sub>4</sub>) is recognized as the most effective drug for the management of eclampsia; this study aims to compare MgSO<sub>4</sub> therapy with diazepam therapy in terms of case fatality rates and costs.</p> <p>Findings</p> <p>This retrospective study, including 1045 patients with eclampsia and pre-eclampsia during the years 2008 and 2009, reports a drop in case fatality rates from 20.9% (95% CI: 18.7, 23.2) to 2.3% (95% CI: 1.4, 3.2) among eclampsia patients following the MgSO<sub>4</sub> intervention. The study observed no significant difference in the cost of using MgSO<sub>4</sub> therapy compared to diazepam therapy.</p> <p>Conclusions</p> <p>The study found a remarkable reduction in case fatality rate due to eclampsia in those who received MgSO<sub>4</sub> therapy with minimal increase in costs when compared to diazepam therapy. Concerted efforts should be focused on properly introducing MgSO<sub>4</sub> into emergency obstetric protocols especially within developing countries to reduce maternal mortality and also impact on health system performance.</p>
topic Magnesium sulphate
Maternal mortality
Millennium Development goals
Northern Nigeria
url http://www.biomedcentral.com/1756-0500/5/421
work_keys_str_mv AT okerekeekechi benefitsofusingmagnesiumsulphatemgsosub4subforeclampsiamanagementandmaternalmortalityreductionlessonsfromkanostateinnorthernnigeria
AT ahonsibabatunde benefitsofusingmagnesiumsulphatemgsosub4subforeclampsiamanagementandmaternalmortalityreductionlessonsfromkanostateinnorthernnigeria
AT tukurjamilu benefitsofusingmagnesiumsulphatemgsosub4subforeclampsiamanagementandmaternalmortalityreductionlessonsfromkanostateinnorthernnigeria
AT ishakusalisu benefitsofusingmagnesiumsulphatemgsosub4subforeclampsiamanagementandmaternalmortalityreductionlessonsfromkanostateinnorthernnigeria
AT oginniayodeji benefitsofusingmagnesiumsulphatemgsosub4subforeclampsiamanagementandmaternalmortalityreductionlessonsfromkanostateinnorthernnigeria
_version_ 1725063874614394880